THE PHARMACOGENETIC MECHANISMS OF DEVELOPMENT OF METABOLIC DISORDERS ASSOCIATED WITH THE SECOND-GENERATION ANTIPSYCHOTICS

DOI: https://doi.org/None

D.V. Ivashchenko (1), R.F. Nasyrova (1), M.V. Ivanov (1), A.E. Taraskina (2), D.N. Sosin (1), K.A. Sosina (1), S.E. Hal'chickiy (1), D.A. Sychev (3), N.G. Neznanov (1) 1 -Saint Petersburg V.M. Bekhterev Research Psychoneurological Institute, Bekhtereva, 3, Saint Petersburg, 192019, Russian Federation; 2 -Pavlov First Saint Petersurg State Medical University, L'va Tolstogo, 6/8, Saint Petersburg, 197022, Russian Federation; 3 -Russian Medical Academy of Postgraduate Education, Barrikadnaya, 2/1, Moscow, 123995, Russian Federation

Antipsychotics are the main medication for schizophrenia treatment. Recently the wideused group of them became second-generation antipsychotics (SGA). Due to that, problem of metabolic disturbances as side effect of SGA is more actually. The development of pharmacogenetics and personalized medicine induced the research of genetic polymorphisms associated with expression of side effects. This review contains results of recent studies of pharmacodynamics genetic factors which influence on metabolic disorders linked with SGA. The transmitter systems of serotonin, dopamine, BDNF, leptin, histamine, neuropeptide Y, epinephrine were considered. Markers for future research were highlighted. Despite of the large evidence base, no one of genetic polymorphisms is not yet considered for implication in clinical practice.
Keywords: 
antipsychotics, metabolic disturbances, pharmacogenetics, weight gain, markers
Список литературы: 
  1. Balt S.L., Galloway G.P., Baggott M.J., Schwartz Z., Mendelson J. Mechanisms and genetics of antipsychotic-associated weight gain. Clin Pharmacol. Ther. 2011; 90 (1): 179–83.
  2. Allison D.B., Mentore J.L., Heo M. et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry. 1999; 156: 1686–96.
  3. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009; 373: 31–41.
  4. Stroup T.S., Lieberman J.A., McEvoy J.P., Swartz M.S., Davis S.M., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K. Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. Am. J. Psychiatry. 2006; 163 (4): 611–22.
  5. Farooqi S., O’Rahilly S. Genetics of obesity in humans. Endocr Rev. 2006; 27 (7): 710–8. Epub 2006 Nov 22.
  6. Xu Y., Jones J.E., Kohno D., Williams K.W., Lee C.E., Choi M.J., Anderson J.G., Heisler L.K., Zigman J.M., Lowell B.B., Elmquist J.K. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron. 2008; 60 (4): 582–9.
  7. Kroeze W.K., Hufeisen S.J., Popadak B.A., Renock S.M., Steinberg S., Ernsberger P., Jayathilake K., Meltzer H.Y., Roth B.L. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003; 28; 519–26.
  8. Perez-Iglesias R., Vazquez-Barquero J.L., Amado J.A., Berja A., Garcia-Unzueta M.T., Pelayo-Terán J.M., Carrasco-Marín E., Mata I., Crespo-Facorro B. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. J. Clin. Psychopharmacol. 2008; 28; 289–95.
  9. Minet-Ringuet J., Even P.C., Valet P., Carpéné C., Visentin V., Prévot D., Daviaud D., Quignard-Boulange A., Tomé D., de Beaurepaire R. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Mol Psychiatry. 2007; 12 (6): 562–71.
  10. Pavan C., Vindigni V., Michelotto L., Rimessi A., Abatangelo G., Cortivo R., Pinton P., Zavan B. Weight gain related to treatment with atypical antipsychotics is due to activation of PKC-β. Pharmacogenomics J. 2010; 10 (5): 408–17.
  11. Gorobec L.N., Bulanov V.S., Vasilenko L.M., Litvinov A.V., Ivanova G.P., Polyakovskaya T.P. Neyrolepticheskie metabolicheskie narusheniya pri lechenii antipsihoticheskimi sredstvami novogo pokoleniya. Zhurn. nevrologii i psihiatrii im. S.S. Korsakova. 2014; 2: 59–68. [Gorobec L.N., Bulanov V.S., Vasilenko L.M., Litvinov A.V., Ivanova G.P., Poljakovskaja T.P. Neuroleptic metabolic dysfunctions in patients treated with new generation antipsychotics. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2014; 2: 59–68 (in Russian)]
  12. Bulanov V.S., Vasilenko L.M. Metabolicheskie rasstroystva, svyazannye s terapiey olanzapinom, i metody ih korrekcii. Obzory po klinicheskoy farmakologii i lekarstvennoy terapii. 2010; 8: 1: 33. [Bulanov V.S., Vasilenko L.M. Metabolic disorders linked with Olanzapin and methods of correction. Obzory po klinicheskoi farmakologii i lekarstvennoi terapii. 2010; 8: 1: 33 (in Russian)]
  13. Gorobec L.N., Ermolaeva L.G., Zhmurina M.V. Problemy uvelicheniya vesa i razvitiya saharnogo diabeta pri neyrolepticheskoy terapii shizofrenii. Sbornik «Metabolicheskie pobochnye e`ffekty i oslozhneniya pri pcihofarmakoterapii». Pod red. I.Ya. Gurovicha i A.B. Shmuklera. Social`naya i klinicheskaya psihiatriya (Prilozhenie). 2003; 22–8. [Gorobec L.N., Ermolaeva L.G., Zhmurina M.V. Problems of the weight gain and diabetes mellitus during the antipsychotics therapy of schizophrenia. Abstract book «Metabolicheskie pobochnye jeffekty i oslozhnenija pri pcihofarmakoterapii» Editorial board: I.Ja. Gurovich and A.B. Shmukler. Social and clinical psychiatry (Suppl.). 2003; 22–8 (in Russian)]
  14. Wang Y.C., Bai Y.M., Chen J.Y., Lin C.C., Lai I.C., Liou Y.J. Polymorphism of the adrenergic receptor A2a-1291C>G genetic variation and clozapine-induced weight gain. J. Neural Transm. 2005; 112, 1463–8.
  15. Park Y.M., Chung Y.C., Lee S.H., Lee K.J., Kim H., Byun Y.C., Lim S.W., Paik J.W., Lee H.J. Weight gain associated with the a2a-adrenergic receptor 1291C/G polymorphism and olanzapine treatment. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2006; 141B, 394–7.
  16. Sickert L., Müller D.J., Tiwari A.K., Shaikh S., Zai C., De Souza R., De Luca V., Meltzer H.Y., Lieberman J.A., Kennedy J.L. Association of the a2A adrenergic receptor-1291 C/G polymorphism and antipsychotic-induced weight gain in European–Americans. Pharmacogenomics. 2009; 10, 1169–76.
  17. De Luca V., Souza R.P., Viggiano E., Sickert L., Teo C., Zai C., Tiwari A.K., Müller D.J., Lieberman J.A., Volavka J., Meltzer H.Y., Kennedy J.L. Genetic interactions in the adrenergic system genes: analysis of antipsychotic-induced weight gain. Hum. Psychopharmacol. 2011; 26 (6): 386–91.
  18. Risselada A.J., Vehof J., Bruggeman R., Wilffert B., Cohen D., Al Hadithy A.F., Arends J., Mulder H. Association between the 1291-C/G polymorphism in the adrenergic α-2a receptor and the metabolic syndrome. J. Clin. Psychopharmacol. 2010; 30 (6): 667–71.
  19. Ujike H., Nomura A., Morita Y., Morio A., Okahisa Y., Kotaka T., Kodama M., Ishihara T., Kuroda S. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J. Clin. Psychiatry. 2008; 69 (9): 1416–22.
  20. Tsai S.J., Yu Y.W., Lin C.H., Wang Y.C., Chen J.Y., Hong C.J. Association study of adrenergic beta3 receptor (Trp64Arg) and G-protein beta3 subunit gene (C825T) polymorphisms and weight change during clozapine treatment. Neuropsychobiology. 2004; 50 (1): 37–40.
  21. Tsai A., Liou Y.J., Hong C.J., Wu C.L., Tsai S.J., Bai Y.M. Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotictreatment. Neuromolecular Med. 2011; 13 (4): 328–33.
  22. Zhang X.Y., Zhou D.F., Wu G.Y., Cao L.Y., Tan Y.L., Haile C.N., Li J., Lu L., Kosten T.A., Kosten T.R. BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology. 2008; 33: 2200–5.
  23. Thorleifsson G., Walters G.B., Gudbjartsson D.F., Steinthorsdottir V., Sulem P., Helgadottir A., Styrkarsdottir U., Gretarsdottir S., Thorlacius S., Jonsdottir I., Jonsdottir T., Olafsdottir E.J., Olafsdottir G.H., Jonsson T., Jonsson F., Borch-Johnsen K., Hansen T., Andersen G., Jorgensen T., Lauritzen T., Aben K.K., Verbeek A.L., Roeleveld N., Kampman E., Yanek L.R., Becker L.C., Tryggvadottir L., Rafnar T, Becker D.M., Gulcher J., Kiemeney L.A., Pedersen O., Kong A., Thorsteinsdottir U., Stefansson K. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat. Genet. 2009; 41 (1): 18–24.
  24. Hong C.J., Liou Y.J., Bai Y.M., Chen T.T., Wang Y.C., Tsai S.J. Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenet Genomics. 2010; 20 (6): 359–66.
  25. Houston J.P., Kohler J., Bishop J.R., Ellingrod V.L., Ostbye K.M., Zhao F., Conley R.R., Poole Hoffmann V., Fijal B.A. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. J. Clin. Psychiatry. 2012; 73 (8): 1077–86.
  26. Lencz T., Robinson D.G., Napolitano B., Sevy S., Kane J.M., Goldman D., Malhotra A.K. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics. 2010; 20 (9): 569–72.
  27. Müller D.J., Zai C.C., Sicard M., Remington E., Souza R.P., Tiwari A.K., Hwang R., Likhodi O., Shaikh S., Freeman N., Arenovich T., Heinz A., Meltzer H.Y., Lieberman J.A., Kennedy J.L. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics J. 2012; 12 (2): 156–64.
  28. Popp J., Leucht S., Heres S., Steimer W. DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. Pharmacogenomics J. 2009; 9 (1): 71–7.
  29. Wirshing D.A., Wirshing W.C., Kysar L., Berisford M.A., Goldstein D., Pashdag J., Mintz J., Marder S.R. Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psychiatry. 1999; 60: 358–63.
  30. Hong C.J., Lin C.H., Yu Y.W., Chang S.C., Wang S.Y., Tsai S.J. Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment. Psychiatr. Genet. 2002; 12 (3): 169–71.
  31. Godlewska B.R., Olajossy-Hilkesberger L., Olajossy M., Limon J., Landowski J. Polymorphisms of the histamine receptor (H1HR) gene are not associated with olanzapine-induced weight gain. J. Clin. Psychopharmacol. 2013; 33 (3): 436–7.
  32. Wu R., Zhao J., Shao P., Ou J., Chang M. Genetic predictors of antipsychotic-induced weight gain: a case-matched multi-gene study. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011; 36 (8): 720–3.
  33. Vehof J., Risselada A.J., Al Hadithy A.F., Burger H., Snieder H., Wilffert B., Arends J., Wunderink L., Knegtering H., Wiersma D., Cohen D., Mulder H., Bruggeman R. Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication. Psychopharmacology (Berl.). 2011; 216 (2): 257–65.
  34. Souza R.P., Tiwari A.K., Chowdhury N.I., Ceddia R.B., Lieberman J.A., Meltzer H.Y., Kennedy J.L., Müller D.J. Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. J. Psychiatr. Res. 2012; 46 (4): 462–8.
  35. Ellingrod V.L., Perry P.J., Ringold J.C., Lund B.C., Bever-Stille K., Fleming F., Holman T.L., Miller D. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am. J. Med. Genet B. Neuropsychiatr. Genet. 2005; 134B (1): 76–8.
  36. Ryu S., Cho E.Y., Park T., Oh S., Jang W.S., Kim S.K., Lee D., Hong K.S. -759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007; 31 (3): 673–7.
  37. Thompson A., Lavedan C., Volpi S. Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone. Psychiatry Res. 2010; 175 (3): 271–3.
  38. De Luca V., Mueller D.J., de Bartolomeis A., Kennedy J.L. Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int. J. Neuropsychopharmacol. 2007; 10 (5): 697–704.
  39. Sicard M.N., Zai C.C., Tiwari A.K., Souza R.P., Meltzer H.Y., Lieberman J.A., Kennedy J.L., Müller D.J. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics. 2010; 11 (11): 1561–71.
  40. Gunes A., Melkersson K.I., Scordo M.G., Dahl M.L. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J. Clin. Psychopharmacol. 2009; 29 (1): 65–8.
  41. Zhang X.Y., Tan Y.L., Zhou D.F., Haile C.N., Cao L.Y., Xu Q., Shen Y., Kosten T.A., Kosten T.R. Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J. Clin. Psychopharmacol. 2007; 27 (3): 246–51.
  42. Gregoor J.G., van der Weide J., Loovers H.M., van Megen H.J., Egberts T.C., Heerdink E.R. Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting. Pharmacogenomics. 2011; 12 (6): 919–23.
  43. Templeman L.A., Reynolds G.P., Arranz B., San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics. 2005; 15 (4): 195–200.
  44. Brandl E.J., Frydrychowicz C., Tiwari A.K., Lett T.A., Kitzrow W., Büttner S., Ehrlich S., Meltzer H.Y., Lieberman J.A., Kennedy J.L., Müller D.J., Puls I. Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2012; 38 (2): 134–41.
  45. Opgen-Rhein C., Brandl E.J., Müller D.J., Neuhaus A.H., Tiwari A.K., Sander T., Dettling M. Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample. Pharmacogenomics. 2010; 11 (6): 773–80.
  46. Perez-Iglesias R., Mata I., Amado J.A., Berja A., Garcia-Unzueta M.T., Martínez García O., Arranz M.J., Vazquez-Barquero J.L., Crespo-Facorro B. Effect of FTO, SH2B1, LEP, and LEPR polymorphisms on weight gain associated with antipsychotic treatment. J. Clin. Psychopharmacol. 2010; 30 (6): 661–6.
  47. Yevtushenko O.O., Cooper S.J., O’Neill R., Doherty J.K., Woodside J.V., Reynolds G.P. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br. J. Psychiatry. 2008; 192 (6): 424–8.
  48. Ellingrod V.L., Bishop J.R., Moline J., Lin Y.C., Miller D.D. Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. Psychopharmacol. Bull. 2007; 40 (1): 57–62.
  49. Ruaño G., Goethe J.W., Caley C., Woolley S., Holford T.R., Kocherla M., Windemuth A., de Leon J. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Mol. Psychiatry. 2007; 12 (5): 474–82.
  50. Yanik T., Kursungoz C., Sutcigil L., Ak M. Weight gain in risperidone therapy: investigation of peripheral hypothalamic neurohormone levels in psychotic patients. J. Clin. Psychopharmacol. 2013; 33 (5): 608–13.
  51. Tiwari A.K., Brandl E.J., Weber C., Likhodi O., Zai C.C., Hahn M.K., Lieberman J.A., Meltzer H.Y., Kennedy J.L., Müller D.J. Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients. J. Clin. Psychopharmacol. 2013; 33 (1): 11–7.
  52. Zhang Q., Deng C., Huang X.F. The role of ghrelin signalling in second-generation antipsychotic-induced weight gain. Psychoneuroendocrinology. 2013; 38 (11): 2423–38.
  53. Smith R.C., Rachakonda S., Dwivedi S., Davis J.M. Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients. Psychiatry Res. 2012; 199 (3): 159–63.
  54. Tiwari A.K., Zai C.C., Likhodi O., Lisker A., Singh D., Souza R.P., Batra P., Zaidi S.H., Chen S., Liu F., Puls I., Meltzer H.Y., Lieberman J.A., Kennedy J.L., Müller D.J. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology. 2010; 35 (6): 1315–24.
  55. Nurmi E.L., Spilman S.L., Whelan F., Scahill L.L., Aman M.G., McDougle C.J., Arnold L.E., Handen B., Johnson C., Sukhodolsky D.G., Posey D.J., Lecavalier L., Stigler K.A., Ritz L., Tierney E., Vitiello B., McCracken J.T. Research Units on Pediatric Psychopharmacology Autism Network. Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. Transl. Psychiatry. 2013; 3: e274.
  56. Monteleone P., Milano W., Petrella C., Canestrelli B., Maj M. Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain. J. Clin. Psychopharmacol. 2010; 30 (4): 441–5.
  57. Graff M., Ngwa J.S., Workalemahu T., Homuth G., Schipf S., Teumer A., Völzke H., Wallaschofski H., Abecasis G.R., Edward L., Francesco C., Sanna S., Scheet P., Schlessinger D., Sidore C., Xiao X., Wang Z., Chanock S.J., Jacobs K.B., Hayes R.B., Hu F., Van Dam R.M.; GIANT Consortium, Crout R.J., Marazita M.L., Shaffer J.R., Atwood L.D., Fox C.S., Heard-Costa N.L., White C., Choh A.C., Czerwinski S.A., Demerath E.W., Dyer T.D., Towne B., Amin N., Oostra B.A., Van Duijn C.M., Zillikens M.C., Esko T., Nelis M., Nikopensius T., Metspalu A., Strachan D.P., Monda K., Qi L., North K.E., Cupples L.A., Gordon-Larsen P., Berndt S.I. Genome-wide analysis of BMI in adolescents and young adults reveals additional insight into the effects of genetic loci over the life course. Hum. Mol. Genet. 2013; 22 (17): 3597–607.
  58. Malhotra A.K., Correll C.U., Chowdhury N.I., Müller D.J., Gregersen P.K., Lee A.T., Tiwari A.K., Kane J.M., Fleischhacker W.W., Kahn R.S., Ophoff R.A., Meltzer H.Y., Lencz T., Kennedy J.L. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch. Gen. Psychiatry. 2012; 69 (9): 904–12.
  59. Czerwensky F., Leucht S., Steimer W. MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain? Int. J. Neuropsychopharmacol. 2013; 16 (9): 2103–9.
  60. Teutsch S.M., Bradley L.A., Palomaki G.E., Haddow J.E., Piper M., Calonge N., Dotson W.D., Douglas M.P., Berg A.O. EGAPP Working Group. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med. 2009; 11 (1): 3–14.